Neratinib


- TRADE NAME: Nerlynx (Puma)
- INDICATIONS: Early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy
- CLASS: Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 7–17 hours
FDA APPROVAL DATE: 07/17/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Aprepitant, Boceprevir, Bosentan, Carbamazepine, Cimetidine, Ciprofloxacin, Clarithromycin, Clotrimazole, Cobicistat, Conivaptan, Crizotinib, Cyclosporine, Dabigatran, Digoxin, Diltiazem, Dronedarone, Efavirenz, Enzalutamide, Erythromycin, Etravirine, Fexofenadine, Fluconazole, Fluvoxamine, Grapefruit Juice, H2-receptor antagonists, Idelalisib, Imatinib, Indinavir, Itraconazole, Ketoconazole, Lansoprazole, Lopinavir, Mitotane, Modafinil, Nefazodone, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong or moderate CYP3A4 inhibitors or inducers, Tipranavir, Tofisopam, Troleandomycin, Verapamil, Voriconazole
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations 
- Breast feeding
- Geriatric
- Pediatric